466 related articles for article (PubMed ID: 27259276)
1. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Barreto R; Waning DL; Gao H; Liu Y; Zimmers TA; Bonetto A
Oncotarget; 2016 Jul; 7(28):43442-43460. PubMed ID: 27259276
[TBL] [Abstract][Full Text] [Related]
2. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
Barreto R; Kitase Y; Matsumoto T; Pin F; Colston KC; Couch KE; O'Connell TM; Couch ME; Bonewald LF; Bonetto A
Sci Rep; 2017 Oct; 7(1):14470. PubMed ID: 29089584
[TBL] [Abstract][Full Text] [Related]
3. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Pin F; Barreto R; Couch ME; Bonetto A; O'Connell TM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):140-154. PubMed ID: 30680954
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
5. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression.
Yang W; Chen Y; Zhang Y; Wang X; Yang N; Zhu D
Cancer Res; 2006 Feb; 66(3):1320-6. PubMed ID: 16452185
[TBL] [Abstract][Full Text] [Related]
6. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
8. Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice.
Chen MC; Hsu WL; Hwang PA; Chen YL; Chou TC
Oncotarget; 2016 Aug; 7(32):51608-51618. PubMed ID: 27323407
[TBL] [Abstract][Full Text] [Related]
9. Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells.
Liu S; Gao F; Wen L; Ouyang M; Wang Y; Wang Q; Luo L; Jian Z
Cell Physiol Biochem; 2017; 43(3):1100-1112. PubMed ID: 28977794
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
11. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
12. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
13. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
14. [Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
Mishima H; Ikenaga M; Yasui M
Nihon Rinsho; 2011 Apr; 69 Suppl 3():554-8. PubMed ID: 22214022
[No Abstract] [Full Text] [Related]
15. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Hebbar M; Tournigand C; Lledo G; Mabro M; André T; Louvet C; Aparicio T; Flesch M; Varette C; de Gramont A;
Cancer Invest; 2006 Mar; 24(2):154-9. PubMed ID: 16537184
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapy in colorectal cancer.
Berlin J
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
